Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas D Ross

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
International Journal of Cancer|November 18, 2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibioticKen Shiozawa, Mikio Oka, Hiroshi Soda, et al.
Molecular Cancer Therapeutics|January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Molecular Pharmacology|May 13, 2010
Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2)Kah Poh Tan, Bernice Wang, Mingdong Yang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|October 1, 2004
Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellowsDouglas D Ross, Deborah Shpritz, Carla S Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
International Journal of Cancer|November 18, 2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibioticKen Shiozawa, Mikio Oka, Hiroshi Soda, et al.
Molecular Cancer Therapeutics|January 12, 2011
Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924Xiaonan Hou, Fei Huang, Joan M Carboni, et al.
Molecular Pharmacology|May 13, 2010
Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2)Kah Poh Tan, Bernice Wang, Mingdong Yang, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|October 1, 2004
Development of required postgraduate palliative care training for internal medicine residents and medical oncology fellowsDouglas D Ross, Deborah Shpritz, Carla S Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Pageof 6